CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Ultragenyx Pharmaceutical Inc.

RARE
$1.47BSmall Cap

Next catalyst

Phase 3January 2027

setrusumab

Osteogenesis Imperfecta, Type I

Get an email about RARE's next catalysts

Track Ultragenyx Pharmaceutical (RARE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline

Catalyst Timeline

2 upcoming, 1 past

Phase 3Next

setrusumab Phase 3 Est. Readout

January 2027~setrusumab6

Estimated primary completion for setrusumab trial (NCT06636071) in Osteogenesis Imperfecta. Topline data typically follows completion by weeks to months.

Source
Phase 3

Triheptanoin Phase 3 Est. Readout

August 2027~Triheptanoin69

Primary completion for Triheptanoin trial (NCT05933200) in Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Source

How RARE's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsBiotechnologyπŸ‡ΊπŸ‡ΈNorth AmericaNOVATO893 employees

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Website
Drug Pipeline

Frequently asked questions

What is in Ultragenyx Pharmaceutical Inc.'s drug pipeline?β†’

CatalystAlert tracks 30 drug candidates in Ultragenyx Pharmaceutical Inc.'s (RARE) pipeline across Phase 3, Phase 2. Its lead program is setrusumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Ultragenyx Pharmaceutical Inc.'s next FDA catalyst?β†’

Ultragenyx Pharmaceutical Inc.'s (RARE) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track RARE biotech catalysts?β†’

Add RARE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ultragenyx Pharmaceutical Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply